Stroke Encounter Quality Improvement Project Annual Meeting 2021






Topics

- State level data
- Registry data 2020
- EMS
- COVID



Leading causes of death in Kentucky, 2019

15 Leading Causes of Death in Kentucky, 2019




15 Leading causes of Death in Kentucky, 2019	Age Adjusted Death Rate	Number of Deaths
Heart Disease	196.4	10742
Cancer	176.4	9975
Accidents (unintentional injuries)	68.1	3121
Chronic lower respiratory diseases	62.4	3517
Cerebrovascular diseases (Stroke)	42.5	2296
Alzheimer disease	32.1	1684
Diabetes mellitus	29.1	1611
Nephritis, nephrotic syndrome and nephrosis		
(Kidney disease)	18.2	. 997
Septicemia	16.7	918
Suicide	16.5	756
Influenza and pneumonia	15.7	850
Chronic liver disease and cirrhosis	13.7	750
Parkinson disease	9.6	507
Essential hypertension and hypertensive renal		
disease	7.1	. 378
Pneumonitis due to solids and liquids	5.1	. 272
anid-E76D118C0E2511502E53231C2E56 on lune 23, 2021		

Source: CDC WONDER Online Database, Accessed at https://wonder.cdc.gov/controller/datarequest/D76;jsessionid=E76D448C9E254A592E53234C2E56 on June 23, 2021

Stroke, Age-adjusted Death Rate, 1999-2019, Kentucky and US

Stroke, Age Adjusted Mortality Rate, 1999-2019 Kentucky and US




Source: CDC WONDER Online Database. Accessed at http://wonder.cdc.gov/ucd-icd10.html on Sept 6, 2021

Stroke, All Ages, All Races, Both Genders, Age Standardized Death rate per 100,000


2007-2009

2017-2019




Source: CDC Interactive Atlas of Heart Disease and Stroke. Accessed at https://nccd.cdc.gov/DHDSPAtlas/?state=County on Sept 7, 2021.

Stroke Death Rate (2017-2019) with overlay of Hospitals having Neurological Services and Telehealth Stroke Care (2019)




Stroke Prevalence in Kentucky, 2018, 18+ ages




Heart Disease, Age-Adjusted Death Rate, Kentucky and US, 1999-2019


Diseases of the Heart, Kentucky versus US, Age-adjusted Mortality Rate, 1999-2019




Heart Disease, Age Standardized Death Rate per 100,000, All Ages, All Races, Both Genders



High Blood Pressure Prevalence among Adults aged 18+, 2017




High Cholesterol Among Adults Screened in Past 5 Years Aged 18+, 2017



Prevalence among adults aged 18+ , 2019	Kentucky (Cl)	US
Adults who have been told they have angina or coronary heart disease	4.9% [4.3-5.6%]	3.9%*
Adults who have been told they had a heart attack (MI)	5.4% [4.8-6.1}	4.3 %*
Adults who have been told they have had a stroke	4.3% [3.7-5.0]	3.2%*
Adults who reported ever having CHD or myocardial infarction (MI)	7.8 [6.9-8.6]	6.3%*
Adults who are current smokers	24.4% [22.8-26.1]	16.0%*
Adults who have been told they have high blood pressure	(37.6%) (36-39.2)	32.3%*
Adults who have been told they have high cholesterol	37.9% (36.1-39.7)	33.1%*
Obesity among adults >=18 years (BMI 30.0-99.8)	36.4 % (34.6- 38.3]	32.1%*
Overweight (BMI 25.0-29.9)	35.4% [33.6 - 37.1]	34.6%*
Overweight or obesity among adults >= 18 years	71.5% [69.7-73.2]	67% (65.5-69]
Adults who have been told they have diabetes	11.7% (10.8-12.6)	10.7%*
Adults who reported having any kind of health care coverage.	91.7% (90.6-92.7}	89.0%*
Adults who have been told they have depression	26.4% (24.7-28)	19.9%*
Alcohol consumption (heavy drinkers, adult men > 14 drinks/week, adult women > 7 drinks/week	6.8% (5.7-7.8)	6.5%*
Did not participate in enough aerobic & muscle strengthening exercises to meet guidelines	83.9% (82.2-85.7)	76.8%*
Did not participate in any physical activities in the past month	31.5% [29.7-33.3)	26.3%


Source: BRFSS Prevalence and Trends Data, 2019. Accessed at cdc.gov/brfss/brfssprevalence/ on June 24, 2021, June 28-29, 2021

SEQIP Registry Data 2020




SEQIP Registry Volume

SEQIP Registry Volume



SEQIP – Patient's Race 2020





SEQIP-Patient's Age

2008-2020 Age Age Percent of Patients Percent of Patients 5(<18 66 - 85 - 45 >85 <18 18 Time Period All KY Hospitals-2020 Time Period

SEQIP – Patient's Gender


SEQIP Patient Gender 2020





2008-2020


Type of Stroke



- Ischemic Stroke
- Subarachnoid Hemorrhage
- Stroke not otherwise specified
- Elective Carotid Intervention only


- Transient Ischemic Attack (< 24 hours)</p>
- Intracerebral Hemorrhage
- No stroke related diagnosis
- Missing data

STK Measure Set



STK Measure Set

IV Thrombolytic Therapy arrive by 2 hours treat by 3 hour



IV Thrombolytic Therapy arrive by 2 hours treat by 3 hour


IV Thrombolytic Arrive by 3.5 Hour, Treat by 4.5 Hour






Time to IV Thrombolytic Therapy < 60 min (DTN < 60 min)

Time to IV Thrombolytic Therapy < 60 minutes




Time to IV Thrombolytic Therapy < 45 min (DTN < 45 min)

Time to IV Thrombolytic Therapy < 45min




Time to IV Thrombolytic Therapy < 30 min (DTN < 30 min)

Time to IV Thrombolytic Therapy < 30 min, 2008-2020




Discharge Disposition 2020

DischargeDisposition - 2020




CSTK Measure Set 2020




CSTK Measure Set

CSTK Measure Set	CSTK Measure Set	Percentage of patients
NIHSS Performed	CSTK-01	92
Modified Rankin Score	CSTK-02	94.6
Severity Measurement Performed for SAH and ICH Patients (Overall Rate)	CSTK-03	79.3
Hunt & Hess Scale Performed	CSTK-03a	83.2
ICH Score Performed for ICH Patients	CSTK-03b	78.2
Procoagulant Reversal Agent Initiation for Intracerebral Hemorrhage (ICH)	CSTK-04	100
Hemorrhagic Transformation (Overall Rate)	CSTK-05	5.8
Hemorrhagic Transformation for Patients Treated with Intra-Venous (IVO) Thrombolytic (alteplase) Therapy only	CSTK-05a	2.5
Hemorrhagic Transformation for Patients Treated with Intra-Arterial (IA) Thrombolytic (alteplase) Therapy or Mechanical Endovascular Reperfusion Therapy	CSTK-05b	7.4
Nimodipine Treatment Administered	CSTK-06	94.7
Thrombolysis in Cerebral Infarction (TICI) Post-Treatment Reperfusion Grade	CSTK-08	89.5
Modified Rankin Score (mRS) at 90 Days: Favorable Outcome	CSTK-10	43.8
Functional Status Prior to Stroke-Independent: IV Alteplase Only	CSTK-10a	45.6
Functional Status Prior to Stroke-Dependent: IV Alteplase Only	CSTK-10b	16.7
Functional Status Prior to Stroke-Independent: MER Therapy	CSTK-10c	
Functional Status Prior to Stroke-Dependent: MER Therapy	CSTK-10d	
Rate of Rapid Effective Reperfusion From Hospital Arrival	CSTK-11	66.3
Rate of Rapid Effective Reperfusion From Skin Puncture	CSTK-12	73.5

CSTK-07 + CSTK 09 Measures



CSTK Measure Set	Total # of patients	Mean Time (minutes)	Standard Deviation	Median (minutes)
Median Time to Revascularization	407	124.9	183.4	103
Arrival Time to Skin Puncture (Overall Rate)	416	142.8	786.9	86
Transferred from another hospital.				
Direct Arrivals				




- Arrival Time to Skin Puncture (Overall Rate)
- ---- Transferred from another hospital.
- -Direct Arrivals


120

In-hospital Mortality by Stroke Type, 2008-2020

In-hospital Mortality by Stroke Type, 2008-2020




All Kentucky Hospitals – Patient Gender & Race, 2020



EMS Pre-notification by Hospital


EMS Pre-notification KY SEQIP Hospitals 2020




Patient transported by EMS, Stroke Screen Performed & Reported, SEQIP hospital data, Jan- Jun 2021

Stroke Screen Performed and Reported

Percentage of confirmed stroke patients transported to your hospital by EMS and for whom a validated regional or national stroke screen tool was used with documentation of the outcome. Time Period: Jan 2021 - Jun 2021; Site: Kentucky SEQIP (42135)



Evaluation of Blood Glucose by EMS, Jan-Jun 2021



Evaluation of Blood Glucose

Percentage of confirmed stroke patients transported to your hospital by EMS and for whom blood glucose was evaluated by EMS.

Query		Date			ber of stroke ne same time	Percentage
COVID-19 vaccine was received prior to admission, not during this hospitalization		May 2020 - Sept 2021	545	13,362		4.1%
Had a medical history of SARS-COV-2 (COVID19)		Mar 2020 – June 2021	184	13,092		1.4%
COVID-19 Vaccine Manufacturer	Number of patients, documented to have received a COVID vaccine (May 2020-Sept 2021)					
AstraZeneca				0		
Johnson & Johnson's / Janssen	25					
Moderna				121		
Novavax				0		
Pfizer	115					
Other	1					
Not Documented				49		
Total				311		



Thank you!